Table 2 Clinical studies of romidepsin (depsipeptide)

I

Advanced or refractory colorectal(11), renal (12)and other neoplasms(14)

Day1 and 5 of a 21-day cycle

24.9 mg/m²

[94]

I

Colorectal(8), breast(4), sarcoma(3) and other (15)

Day1, 8, and 15 of 28-day cycle

13.3 mg/m²

[95]

I

CLL/AML(20)

Day1, 8, and 15 of 28-day cycle

13 mg/m²

[98]

I

Gemcitabine

Solid tumor(33)

Days 1, 8, and 15 of a 28 day cycle

12 mg/m²

[101]

I

Solid tumors(26)

Days 1,3, and 5 of a 28-day cycle

9 mg/m²

[100]

II

Renal cell carcinoma(42)

days 1, 8, and 15 of a 28-day cycle

13 mg/m².

OR 7%.

[96]

I-II

MDS(3)/AML(9)

Day 1 and 5 of a 21-day cycle

18 mg/m² (CR .6%, SD 46%, POD 30.7%, NA 7.6%).

[99]

II

SCLC(3)/NSCLC(16)

Day 1 and 7 of a 21 day cycle

SD52%, POD 48%.

[97]